Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

FDA clears TAVR guidewire built with BASILICA in mind
The Telltale system was designed to assist cardiologists when BASILICA is required prior to TAVR.
New technique could help when cardiologists repair 2 leaky heart valves at once
Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.
‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations
The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward.
Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in
Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?
New physician Medicare payments for the Agent drug-coated balloon set for 2027
Boston Scientific said two category III CPT codes are set to become permanent category I codes for physician payments starting Jan. 1, 2027.

TEER still beneficial for heart failure patients with an elevated mitral valve gradient

Researchers explored data from the COAPT trial, sharing their findings in JACC: Cardiovascular Interventions.

M&A mergers and acquisitions business deal

Endologix acquires medical device company focused on peripheral artery disease

PQ Bypass, the company Endologix acquired, has gained significant attention for its Detour platform, an investigational treatment for percutaneous femoral-popliteal bypass.

Uninterrupted OAC therapy for PCI patients leads to cost savings, shorter lengths of stay

Putting OAC therapy on hold does have its own benefits, the authors wrote, but uninterrupted OAC therapy is still the better choice.

New guidelines focus on the management of heart failure patients with secondary mitral regurgitation

The Heart Failure Association, European Association of Cardiovascular Imaging, European Heart Rhythm Association and European Association of Percutaneous Cardiovascular Interventions all collaborated on the position statement.

Abbott gains CE mark approval for short-term DAPT after stent implantation in high-risk patients

Abbott is currently seeking a similar approval from the FDA.

Championing Alternative PAD Access in the Office-based Lab

Sponsored by Terumo

Improving access is at the center of a pair of new trends in treating peripheral artery disease (PAD). First is the office-based lab (OBL) expanding access to more PAD patients needing therapy, and the second is physicians more often choosing alternative access such as radial, tibial or pedal to treat those patients. Why now?

Primary PCI boosts 10-year survival rate for STEMI patients

STEMI mortality remains a primary concern among healthcare providers, and a new study in the American Journal of Cardiology suggests that long-term outcomes are much better if the patient undergoes primary PCI.

Frail patients much more likely to experience major bleeding events following PCI

The new study, published by the American Journal of Cardiology, suggests that frailty could be a helpful predictor for major bleeding events after PCI.

Interventional Cardiology

FDA clears TAVR guidewire built with BASILICA in mind

New technique could help when cardiologists repair 2 leaky heart valves at once

‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations

Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in

New physician Medicare payments for the Agent drug-coated balloon set for 2027